Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Attention Deficit Hyperactivity Disorder, ADHD
Interventions: Methylphenidate Hydrochloride Extended Release Capsules, Placebo; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: Little Rock, Arkansas • Irvine, California • National City, California + 13 more

Conditions: Memory Disorders
Interventions: Celecoxib; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: PL-3994; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cranbury, New Jersey

Conditions: Normal Physiology
Interventions: continuous Theta Burst Stimulation (cTBS), intermittent Theta Burst Stimulation (iTBS), sham Theta Burst Stimulation (sham TBS); Device
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2044
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acid Reflux Disease, Obstructive Sleep Apnea
Interventions: Pantoprazole; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: CYT003, Placebo; Biological
Lead sponsor: Cytos Biotechnology AG; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alzheimer's Disease
Interventions: ABT-126, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 55 Years to 90 Years
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Fresno, California • Long Beach, California • San Francisco, California + 8 more

Conditions: Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Anxiety Disorder
Interventions: Attentional Bias Modification Treatment (ABMT) - Active, Attentional Bias Modification Treatment - Placebo, Cognitive Behavioral Group Therapy, Psychoeducational Control Intervention; Other · Behavioral
Lead sponsor: Hospital de Clinicas de Porto Alegre; Other
Eligibility: 7 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Preterm Birth, Pregnancy, Multifetal
Interventions: 17 alpha-hydroxyprogesterone caproate (17P); Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 795 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 14
States / cities: Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more

Conditions: Nutrient Deficiency
Interventions: Pharmavite Nature Made Multi for Him 50+, Placebo; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Preterm Birth
Interventions: Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: NGM282, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 36
States / cities: Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 28 more

Conditions: Headache, Tension-Type
Interventions: Placebo, Experimental paracetamol + caffeine formulation, ibuprofen marketed formulation, Paracetamol marketed formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Pembroke Pines, Florida • Springfield, Massachusetts • Wellesley Hills, Massachusetts + 4 more

Conditions: Prostate Cancer Prevention
Interventions: SFN-rich broccoli sprout extract capsules, Gelatin capsule containing microcrystalline cellulose.; Drug · Dietary Supplement
Lead sponsor: Portland VA Medical Center; Federal
Eligibility: 21 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Prediabetic State, Hyperglycemia
Interventions: Zinc Gluconate 30 MG, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Anorexia Nervosa, Osteoporosis
Interventions: Placebo, Teriparatide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 70 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Use Disorder, Cigarette Smoking
Interventions: Semaglutide, Sham/placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Elderly
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: South Miami, Florida

Conditions: Vitiligo
Interventions: AMG 714, Placebo, nbUVB phototherapy; Biological · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Irvine, California • Sacramento, California • New Haven, Connecticut + 4 more

Conditions: Lung Cancer
Interventions: carboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 400
States / cities: Anniston, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 266 more

Conditions: Clostridium Difficile Associated Disease
Interventions: C. difficile vaccine, C. difficile vaccine +adjuvant; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more

Conditions: Sleep Disorders, Circadian Rhythm
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 39 more

Conditions: Insomnia, Nicotine Dependence
Interventions: Eszopiclone, Bupropion; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Driving Behavior
Interventions: Hazard Perception Training, Vehicle Maintenance Training, Attention Maintenance Training; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 15 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making

Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children

Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)

Vitamin and Mineral Supplementation Improves Micronutrient Status in Older Adults

Assessment of DHA On Reducing Early Preterm Birth

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

Paracetamol With Caffeine to Treat Episodic Tension Type Headache

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

Effect of Zinc on Glucose Homeostasis

The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

Semaglutide for Alcohol Use Disorder

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

Evaluation of AMG 714 for Vitiligo

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

Washington State Driving Intervention Research Study